The effect of combined oral contraceptives and age on dysmenorrhoea: an epidemiological study

2012 ◽  
Vol 2012 ◽  
pp. 267-268
Author(s):  
L.P. Shulman
Keyword(s):  
Epidemiological Study ◽  
Oral Contraceptives ◽  
Combined Oral Contraceptives

Migraine and oral contraception

1987 ◽  
Vol 25 (24) ◽  
pp. 95-96
Keyword(s):  
Epidemiological Study ◽  
Oral Contraceptives ◽  
Oral Contraception ◽  
Combined Oral Contraceptives ◽  
Medical Factors ◽  
Contraceptive Choice

In our article on medical factors in contraceptive choice1 we did not consider whether migraine should limit the prescription of combined oral contraceptives. A relationship has long been suspected and a good epidemiological study is long overdue.

Platelet Adhesiveness in Symptomatic Women Taking Oral Contraceptives

1971 ◽  
Vol 26 (03) ◽  
pp. 426-430 ◽  
Author(s):  
T. F Zuck ◽  
J. J Bergin ◽  
Jane M. Raymond ◽  
W. R Dwyre ◽  
D. G Corby
Keyword(s):  
Oral Contraceptives ◽  
Platelet Adhesiveness ◽  
Combined Oral Contraceptives ◽  
Increased Risk ◽  
Normal Women ◽  
Asymptomatic Women

SummaryPlatelet adhesiveness to glass was determined in several groups of women. Increases were found in women developing thrombovascular symptoms while taking combined oral contraceptives, compared to both normal women and asymptomatic users of oral contraceptives. Despite this increase, overlap of the groups did not permit discrimination between symptomatic and asymptomatic women. However, it is possible, that in concert with other coagulation changes, platelet adhesiveness to glass may prove adjunctive in defining women at increased risk of developing thrombovascular symptoms while taking oral contraceptives, and further define the mechanism of the increased risk.

HAEMOSTATIC CHANGES INDUCED BY TWO LOW DOSE TRIPHASIC ORAL CONTRACEPTIVES

1987 ◽  
Author(s):  
S J Machin ◽  
I J Mackie ◽  
K Walshe ◽  
M D Gillmer
Keyword(s):  
Oral Contraceptives ◽  
Protein C ◽  
Low Dose ◽  
Factor Vii ◽  
Cycle Period ◽  
Factor Xii ◽  
Factor X ◽  
Combined Oral Contraceptives ◽  
First Time ◽  
Protein C Activity

The haemostatic system was investigated in 26 women taking cyclically administered triphasic combined oral contraceptives for the first time during their first six cycles. Fourteen women received Logynon (mean dose 32.4μg ethinyloestradiol, 92pg progestagen) and 12 received SHD 415G (Schering) which contains a mean dosage of 32.4μg ethinyloestradiol and 78pg gestodene, a recently developed progesterone. The Logynon group showed a significant increase (p<0.005) in fibrinogen (pre-mean 284.4 g/1; after 1 cycle 347.3 g/1, after 6 cycles 318.6 g/1) , factor VII (65.8 u/1 to 73.9 u/1 to 83.2 u/1), factor XII (1.74 u/1 to 2.41 u/1, to 2.25 u/1), plasminogen (100.9 u/1 to 135.1 u/1 to 126.3 u/1); decrease in ATIII (115.9 u/1 to 103.1 u/1 to 93.4 u/1) but no significant change in factor X (98.4 u/1 to 108.9 u/1 to 102.4) or protein C (0.85 u/1 to 0.88 u/1 to 0.94 u/1) activity. The SHD 415G group showed similar changes with an increase in fibrinogen (247.9 g/1 to 330.8 g/1 to 373 .1 g/1), factor VII (63.1 u/1 to 73.1 u/1 to 90.3 u/1, factor X (98.3 u/1 to 112.0 u/1 to 124.4 u/1), factor XII (1.46 u/1, to 1.93 u/1, to 2.03 u/1), plasminogen (110.8 u/1 to 125.4 u/1 to 136.7 u/1); decrease in ATIII (113.1 u/1 to 96.3 u/1 to 89.7 u/1), but no change in protein C (0.84 u/1 to - 0.78 u/1 to 0.85 u/1) activity. These changes were apparent after the first cycle of therapy and the differences were maintained over the six cycle period. There was no increase in protein C activity despite changes in the other vitamin K dependent proteins factors VII and X. Both low oestrogen dose triphasic pills caused similar prothrombotic changes which were not modified by the new progesterone, gestodene.

scholarly journals Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives

2015 ◽  
Vol 39 (5) ◽  
pp. 441-445 ◽  
Author(s):  
Susan J. Jordan ◽  
Louise F. Wilson ◽  
Christina M. Nagle ◽  
Adele C. Green ◽  
Catherine M. Olsen ◽  
...  
Keyword(s):  
Oral Contraceptives ◽  
Combined Oral Contraceptives

Quantitation of Albumin and Alpha-1-Acid Glycoprotein in Human Cervical Mucus

1991 ◽  
Vol 10 (2) ◽  
pp. 137-139 ◽  
Author(s):  
I.G. Salas Herrera ◽  
R.M. Pearson ◽  
P. Turner
Keyword(s):  
Oral Contraceptives ◽  
Genital Tract ◽  
Female Genital Tract ◽  
Cervical Mucus ◽  
Combined Oral Contraceptives ◽  
Acid Glycoprotein ◽  
Group A ◽  
The Mean ◽  
Group B ◽  
Female Genital

1 Concentrations of albumin and alpha-1-acid glycoprotein (AGP) in human cervical mucus have been measured by a radial immunodiffusion technique. 2 The cervical mucus samples were obtained from women on combined oral contraceptives (Group A) and from women not taking this medication (Group B). In group A the mean level of albumin was 75.6 (range 22-198) mg 1-1 and for AGP 6.5 (range 3-12) mg 1-1. In group B the mean level of albumin was 72.9 (range 22-148) mg 1-1 and for AGP 6.6 (range 3-14) mg 1 -1. 3 The levels of albumin and AGP in cervical mucus were less than 1% of the concentration in serum and were not affected by combined oral contraceptives. 4 The clinical and toxicological consequences of these observations, in terms of the disposition of drugs and other chemicals in the female genital tract, await elucidation.

Sign in / Sign up

Export Citation Format

Share Document